𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China

✍ Scribed by Guang Bi YAO; Mei ZHU; Zhen Yu CUI; Bao En WANG; Ji Lu YAO; Ming De ZENG


Book ID
111414435
Publisher
Wiley (Blackwell Publishing)
Year
2009
Tongue
English
Weight
160 KB
Volume
10
Category
Article
ISSN
1751-2972

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Efficacy of lamivudine in patients with
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Hepatitis B e antigen as a predictor for
✍ En-Qiang Chen; Hong Tang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB 👁 2 views

PROVE1 trial, 1 in which in the group with an identical treatment schedule, the percentage of patients obtaining SVR with respect to RVR was 75% only. In other words, RVR seems easier to obtain with telaprevir, but less frequently predicts a favorable treatment outcome. A possible explanation might

The absence of hepatitis B virus DNA in
✍ Janet S. Scott; Pei-En Pan; Raymond A. Pace; Theo P. Sloots; Prof. W. Graham Coo 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 2 views

## Abstract Sera from 20 Chinese patients with chronic hepatitis B were examined for hepatitis B e antigen and hepatitis B virus (HBV) DNA. There was considerable discordance with HBV DNA not being detectable in 10 out of 13 (77%) patients who were hepatitis B e antigen positive. Further testing fo